Visualization and Quantitative Measurement of Drug-Induced Platinum Adducts in the Nuclear DNA of Individual Cells by an Immuno-Cytological Assay

  • Margarita Melnikova
  • Jürgen ThomaleEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1655)


Immunocytological staining with adduct-specific antibodies allows the visualization and measurement of structurally defined types of DNA damage in the nuclei of individual cells. Here we describe an immunocytological assay (ICA) procedure for the localization and quantification of such damage, in particular induced by platinum-based anticancer drugs, in cell lines, in primary cell suspensions and in frozen tissue sections.

Key words

DNA adducts Cisplatin Monoclonal antibody Immunofluorescence Single cell analysis Quantitative image analysis 



We thank Maria Eynck (IFZ) for excellent technical assistance.


  1. 1.
    Wheate NJ, Walker S, Craig GE et al (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39:8113–8127CrossRefPubMedGoogle Scholar
  2. 2.
    Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320CrossRefPubMedGoogle Scholar
  3. 3.
    Ziehe M, Esteban-Fernández D, Hochkirch U et al (2012) On the complexity and dynamics of in vivo Cisplatin-DNA adduct formation using HPLC/ICP-MS. Metallomics 4:1098–1104CrossRefPubMedGoogle Scholar
  4. 4.
    Galluzzi L, Vitale I, Michels J et al (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5:e1257CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Liedert B, Pluim D, Schellens J et al (2006) Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 34:e47CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Liedert B, Materna V, Schadendorf D et al (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121:172–176CrossRefPubMedGoogle Scholar
  7. 7.
    Barr M, Gray SG, Hoffmann AC et al (2013) Generation and characterization of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8:e54193CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dzagnidze A, Katsarava Z, Makhalova J et al (2007) Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 27:9451–9457CrossRefPubMedGoogle Scholar
  9. 9.
    Oliver TG, Mercer KL, Sayles LC et al (2010) Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24:837–852CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Jokić M, Vlašić I, Rinneburger M et al (2016) Ercc1 deficiency promotes tumorigenesis and increases Cisplatin sensitivity in a Tp53 context-specific manner. Mol Cancer Res 14:1110–1123CrossRefPubMedGoogle Scholar
  11. 11.
    Zivanovic O, Abramian A, Kullmann M et al (2015) HIPEC ROC I: a phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 136:699–708PubMedGoogle Scholar
  12. 12.
    Nel I, Gauler TC, Eberhardt WE et al (2013) Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumor cells and response to platinum treatment. Br J Cancer 109:1223–1329CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sorg UR, Kleff V, Fanaei S et al (2007) O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues. DNA Repair (Amst) 6:1197–1209CrossRefGoogle Scholar
  14. 14.
    Thomas JP, Lautermann J, Liedert B et al (2006) High accumulation of platinum–DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharmacol 70:23–29PubMedGoogle Scholar
  15. 15.
    Kobayashi N, Katsumi S, Imoto K et al (2001) Quantitation and visualization of ultraviolet-induced DNA damage using specific antibodies: application to pigment cell biology. Pigment Cell Res 14:94–102CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  1. 1.Institute of Cell Biology (Cancer Research)University of Duisburg-Essen Medical SchoolEssenGermany

Personalised recommendations